Clinical Trial

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Study acronym: MS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-23; most recent amendment 2025-11-19.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-11-19
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-04-01
Trial Details
NCT Number NCT06800404
Lead Sponsor Hope Biosciences Research Foundation
Conditions Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Enrollment 10 participants
Start Date 2025-05-02
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-20